Physician profile
Tony Dang
NPI 1083795199
$1,388.72
in general payments reported to CMS, 2019-2025
22 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.30 · 2020: $345 · 2021: $39.34 · 2022: $78.19 · 2023: $211 · 2024: $209 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $181.83 | 2019-2024 | Jardiance |
| Abbott Laboratories | $172.53 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $145.26 | 2020 | |
| Exact Sciences Corporation | $130.67 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $123.68 | 2023 | Vemlidy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.67 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $85.32 | 2020-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $65.97 | 2025 | Ozempic |
| Hologic Sales and Service, LLC | $63.20 | 2025 | Aptima |
| Horizon Therapeutics Plc | $47.77 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $43.53 | 2025 | |
| Pfizer INC. | $41.95 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $27.57 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $25.73 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $23.30 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.64 | 2025 | Otezla, Repatha |
| Axonics, INC. | $19.05 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.58 | 2019 | |
| Cranial Technologies, INC | $15.91 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.88 | 2025 | Airsupra |
| Merck Sharp & Dohme LLC | $14.72 | 2019 | |
| Mannkind Corporation | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.